Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
Type:
Application
Filed:
March 27, 2012
Publication date:
July 5, 2012
Applicant:
INNOPHARMA, LLC
Inventors:
Kumaresh Soppimath, Satish Pejaver, Kanaiyalal R. Patel, Lakkaraju Dasaradhi, Rama Sodum, Hari Desu, Navneet Puri
Abstract: Multi-dose formulations for bortezomib are presented in which bortezomib has significantly improved stability. Especially preferred formulations include those in which bortezomib is in a liquid form suitable for injection, wherein the solvent system predominantly comprises propylene glycol. In other preferred aspects, bortezomib is present as a Lewis donor-acceptor complex with a hetero-bifunctional Lewis base.
Type:
Application
Filed:
March 18, 2011
Publication date:
September 22, 2011
Applicant:
INNOPHARMA, LLC
Inventors:
Kumaresh Soppimath, Satish Pejaver, Kanaiyalal R. Patel, Lakkaraju Dasaradhi, Rama Sodum, Hari Desu, Navneet Puri
Abstract: The present invention provides methods and compositions for delivery of taxanes in stable oil-in-water emulsion. The inventive emulsion formulation includes an oil phase, aqueous and emulsifier phases. The oil portion includes all or substantial amount of taxane, vegetable oil and medium chain triglycerides; aqueous phase includes an emulsion stabilizer; emulsifier phase reduces the surface tension between oil and aqueous phases to produce a stable oil-in-water emulsion. The inventive compositions produce minimal side effects upon administration.
Type:
Application
Filed:
January 7, 2011
Publication date:
July 7, 2011
Applicant:
INNOPHARMA, LLC
Inventors:
HARI R. DESU, KANAIYALAL R. PATEL, SATISH K. PEJAVER, NAVNEET PURI
Abstract: The present invention provides a composition and prodrug for targeted drug delivery to the central nervous system of a patient. The inventive composition and prodrug include a pharmaceutically acceptable active agent and at least one protein selected from the group consisting of a fimbrial adhesin protein, a membrane protein, and combinations thereof. The inventive compositions and prodrugs of the present invention selectively target the blood-brain barrier and deliver hydrophilic and lipophilic active agents of varying sizes to the central nervous system.
Type:
Application
Filed:
March 26, 2010
Publication date:
December 30, 2010
Applicant:
InnoPharma, LLC
Inventors:
Vishal Soni, Kanaiyalal R. Patel, Dasaradhi Lakkaraju, Navneet Puri